Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

This article provides an overview of developments in advanced prostate cancer and considers how the available options for lengthening survival for men with mCRPC may be sequenced.

Treating Prostate ... cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ... Precision Therapy for Metastatic Prostate Cancer Improves ...

Prostate cancer ranks among the most common health challenges men face worldwide. While medical advances continue to improve treatment outcomes, the e ...

Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...

Discover the study supports the potential of neoadjuvant androgen deprivation therapy as an adjunctive therapy in HRLPC.

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase ...

Brain metastases from prostate cancer (PC) seem to be more frequent ... patients with castration-resistant PC have prolonged their survival. Furthermore, docetaxel (the drug of choice for the ...

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...

Breast cancer ... survival rate. The range of options for therapy in breast cancer depends on the stage and when it is discovered. Among those options are radiation therapy, surgery, and hormone ...

The success of CAR T cell therapies against solid ... by rimiducid in patients with metastatic pancreatic or prostate cancer.